Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in multiple myeloma a billion market by | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
35 of 64
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
March 2024
responses in amyloidosis market at ash immi | Immix Biopharma
Investor Presentation
January 2024
clinical results demonstrate potential for best in class efficacy safety in light chain amyloidosis | Immix Biopharma
Investor Presentation
January 2024
first car in amyloidosis a billion market by i i | Immix Biopharma
Investor Presentation
December 2023
clinical results demonstrate potential for best in class efficacy safety in multiple myeloma a billion market by class leading | Immix Biopharma
Related slides by other companies
ATAI
Investor Presentation
January 2024
clinical evidence efficacy on cognitive in a phase study | ATAI
ATAI
Investor Presentation
March 2023
low doses enhanced learning and memory significantly reverses memory deficits memory challenged young dogs phase scopolamine memory challenge clinical and non clinical studies provide consistent evidence of pro cognitive effect along inverted bell shaped dose response curve learnings in reversed in | ATAI
ATAI
Investor Presentation
January 2024
clinical evidence efficacy signals reproduced in phase a study in | ATAI
ATAI
Investor Presentation
October 2023
clinical evidence efficacy signals reproduced in phase a study in | ATAI
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
March 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights